secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-04-29T23:59:59+00:00
Accession:  0001564590-22-016548
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma stockholders approve doubling authorized shares to 85M
------------------------------------------------------------------

- Stockholders approved increase in authorized common shares from 42.5M to 85,000,000.
- Amendment to 2015 Stock Plan approved, increasing reserved shares by 2,000,000.
- Amendment to 2015 ESPP approved, increasing reserved shares by 750,000 and per-employee limit to 2,500.
- All three Class I director nominees elected (John Clarke, Paul Schimmel, Sara Zaknoen).
- Ratification of Ernst & Young as auditor and advisory approval of executive compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/0001564590-22-016548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/life-8k_20220426.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-016548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer